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The American Journal of Pathology has developed a formal Scientific Integrity Policy in 
an effort to define more clearly issues of scientific misconduct in journal publishing. This 
document defines common issues relating to appropriate scientific conduct as well as the 
procedures that will be followed should misconduct issues arise. In addition the 
Instructions to Authors (http://www.journals.elsevierhealth.com/ 
periodicals/ajpa/authorinfo) and Instructions to Reviewers (http://www.journals. 
elsevierhealth.com/periodicals/ajpa/content/reviewers) have been updated to reflect these 
changes.  
The policy is based on recommendations from the Uniform Requirements for Manuscripts 
Submitted to Biomedical Journals (http://www.icmje.org), the CSE White Paper on 
Promoting Integrity in Scientific Journal Publications 
(http://www.councilscienceeditors.org/editorial_policies/white_paper.cfm), and the US 
Department of Health and Human Services’ Office of Research Integrity 
(http://ori.dhhs.gov/). It should be noted that willful misconduct does not include incidents 
of honest misjudgment or inadvertent error. Any questions regarding the official policy of 
the Journal should be directed to the Editorial Office at 301-634-7959 or ajp@asip.org. 
Author Conduct 
General Authorship Guidelines. Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals (http://www.icmje.org) defines authorship as “1) substantial 
contributions to conception and design, or acquisition of data, or analysis and 
interpretation of data; 2) drafting the manuscript or revising it critically for important 
intellectual content; and 3) final approval of the version to be published. Authors should 
meet conditions 1, 2, and 3.” When work has been performed by a large, multi-center 
group, the group should designate individuals who accept direct responsibility for the 
manuscript on behalf of the group. These individuals should fully meet the criteria above 
and should disclose conflicts of interest (see below) on behalf of the group. All members 
of the group who meet authorship criteria should be provided for listing as a footnote.  
When submitting a manuscript to the Journal, the corresponding author takes 
responsibility on behalf of all authors for the authorship, authenticity and integrity of the 
research being reported. The email contact information of ALL authors is required so the 
Journal may formally contact the authors regarding any aspect of manuscript submission. 
If an author is removed during the course of revision of the manuscript, written explanation 
and consent by the removed author (signed letter or personal email) should be provided. 
Any change made to the list of authors (addition, removal, change in order) after 
manuscript acceptance requires consent of all authors and editorial approval. Authorship 
disputes are to be resolved by the authors and/or their institutions, not by the Journal. 
Because inclusion in the Acknowledgments may give the appearance of endorsement of 
the manuscript and its findings, authors should obtain permission from all individuals 
named in the Acknowledgments who contributed substantially to the work reported (eg, 
data collection, analysis, or writing/editing assistance) but did not fulfill the authorship 
criteria. Likewise, authors should receive permission from all individuals named as 
sources for personal communication or unpublished data. Such permissions should be 
affirmed by the corresponding author in the cover letter.  
Ghostwriting. As stated above, all persons contributing to the paper but not meeting 
authorship criteria should be listed in the Acknowledgments section. Further, any funding 
for writing support should be fully disclosed. If an outside source funded the assistance, 
the authors of the paper should also affirm that they are solely, and independently, 
responsible for the interpretation of the data and that they had full and open access to all 
of the data. It is considered unethical for any entity (eg, governmental, private, or 
commercial) with direct financial or personal interests to restrict the use of data or their 
interpretation for the sole purpose of presenting data in a manner that is favorable to its 
own interests or those of its affiliates. It is also unethical for any entity to be responsible for 
data gathering, interpretation, and/or presentation and then to solicit outside "authors" for 
the paper, as a means of hiding its relationship with the data.  
Peer Review Process. The Journal takes great care to secure the confidentiality and 
integrity of the peer-review process. It is the practice of the Journal to conduct a blinded 
peer-review process. Thus, it is considered a violation of this process for authors to identify 
or attempt to communicate directly with peer reviewers or Associate Editors regarding 
their manuscript. The Editors will consider any deliberate ethical violation in either the 
reported research or the manuscript preparation and review to be actionable misconduct, 
the potential results of which may be manuscript rejection or public article retraction, 
reporting of conduct to the authors’ governing institutions, and/or the denial to consider 
any future submissions to the Journal.  
Authors may request that specific reviewers not be used due to prior collaborations, 
known conflicts of interest, or direct competition. The Editors will make every effort to 
respect requests that are well-founded; however, the Editors do have the authority to 
utilize such a reviewer if it is necessary for expert peer review.   
To aid the review process, authors should be ready to comply with Editors’ requests for 
copies of any similar works in preparation, copies of cited manuscripts that are submitted 
or in press, and/or supporting manuscript data (eg, data not shown but summarized in the 
manuscript). Failure to do so may result in rejection of the manuscript without further 
review.  
Financial Disclosure and Conflicts of Interest. All authors must disclose any current or 
former relationships (eg, employment, consultancies, board membership, stock ownership, 
funding, honoraria, expert testimony, patents or royalties, travel reimbursements, industry-
supplied free reagents, etc) with any organization or entity having a direct financial or 
personal interest in the subject matter or materials discussed in the manuscript. Authors 
should err on the side of full disclosure and should contact the Editorial Office if they have 
questions or concerns. This information should be provided at the time of submission (for 
new and revised manuscripts). All authors will be required to complete an online 
disclosure form following acceptance; details are provided in the acceptance letter. Failure 
to disclose conflicts of interest may result in manuscript rejection or editorial retraction of 
the article. 
Ethical Treatment of Research Subjects. If human subjects or samples were used, 
authors must affirm that the research protocol was approved by the appropriate 
institutional review boards or ethics committees for human (including use of human cells 
or tissues) experiments and that all human subjects provided appropriate informed 
consent. To protect patient privacy, identifying information such as names, initials, or 
hospital numbers should not be published unless the information is essential for scientific 
purposes and the patient (or parent or guardian) gives written informed consent for 
publication. If race/ethnicity is reported, authors should state who determined 
race/ethnicity, how the options were defined, and why race/ethnicity was important in the 
study. Authors should be prepared to provide study protocol number(s) if requested. 
Ethical Treatment of Animals. If animal experiments were performed, authors must 
affirm that the research protocol was approved by the appropriate institutional review 
boards or ethics committees for animal experiments and that regulations concerning the 
use of animals in research were adhered to. Authors should be prepared to provide study 
protocol number(s) if requested. 
Copyright. Copyright of published manuscripts is held by the American Society for 
Investigative Pathology, which must receive the assignment of copyright from the authors 
of accepted manuscripts. For US government employees, the above assignment applies 
only to the extent allowable by law. See http://www.asip.org/pubs/ajprights.pdf for details. 
Requests to republish copyrighted materials, including the planned use, should be 
directed to the Editorial Office at 301-634-7959 or ajp@asip.org. 
Publishing in The American Journal of Pathology automatically places authors in 
compliance with NIH Public Access Policy (see http://publicaccess.nih.gov/ 
submit_process.htm, Submission Method A). Any article noted as being funded by NIH, 
HHMI, Wellcome Trust, or MRC is deposited in PubMed Central (PMC), to be made 
available to the public twelve months after final print publication (unless the funding 
agency stipulates a sooner release date). Authors therefore should NOT complete a 
separate deposit of their material but will be contacted by PubMed Central for grant 
verification once the article has been received by the PMC article system. For information 
on how to cite articles in NIH grant applications, please visit 
http://www.asip.org/pubs/AuthorNotice.cfm. 
Contact healthpermissions@elsevier.com regarding permission to deposit manuscripts in 
other government-sponsored repositories in cases where The American Journal of 
Pathology does not have a system in place to automatically deposit materials on behalf of 
their authors. Deposit of accepted or published manuscripts in any non-AJP repository 
without prior permission by the Journal is a violation of copyright. 
Embargo Policy. All information regarding the content of submitted or accepted 
manuscripts is strictly confidential. Information contained in or about accepted articles 
cannot appear in print, audio, video, or digital form or be released by the news media until 
the Journal embargo date has passed, not to exceed the publication date of the article. 
For detailed information on embargo release dates or for news media requests for preprint 
copies of specific articles, contact asipproduction@elsevier.com. 
Scientific Misconduct. According to the US Office of Research Integrity 
(http://ori.dhhs.gov/), “fabrication is making up data or results and recording or reporting 
them; falsification is manipulating research materials, equipment, or processes, or 
changing or omitting data or results such that the research is not accurately represented in 
the research record; plagiarism is the appropriation of another person's ideas, processes, 
results, or words without giving appropriate credit.” The Journal has a zero tolerance 
policy for such matters. For details regarding how the Journal handles such matters, see 
the later section on Allegations of Misconduct.  
Fabrication of Data. Any evidence of fraudulent methods, data, or data analysis may 
prompt the Editors to request an explanation and access to original data, which the 
authors must supply.  
Falsification of Data. The results presented in the manuscript must accurately represent 
the data obtained in the course of authors’ studies; omission of contradictory or negative 
data in an effort to support the main hypothesis is unacceptable. Taking photographs of 
the same source under varied fields of view, light intensity, magnifications, or contrast 
conditions without disclosing that the data are not unique to the present study constitutes 
suspect scientific conduct. Further, unless serial sections are used, the publication of 
identical-appearing images labeled with different staining techniques in different papers 
raises legitimate questions. No specific feature within an image may be enhanced, 
obscured, moved, removed, or introduced. The grouping of images from different parts of 
the same gel or blot, or from different gels or blots, fields, or exposures must be made 
explicit by the arrangement of the figure (eg, using dividing lines) and in the figure legend. 
Adjustments of brightness, contrast, or color balance are acceptable only if they are 
applied to the whole image, whether experimental or control image, and as long as they 
do not obscure or eliminate any information present in the original (Portions adapted with 
permission from the JCB). Any evidence of inappropriate manipulation may prompt the 
Editors to request an explanation and access to original data, which the authors must 
make available.  
Plagiarism. Authors should carefully note that the use of another person’s data or ideas 
without permission constitutes plagiarism. Authors may not republish copyrighted Journal 
material in whole or in part without the express permission of the copyright holder, the 
American Society for Investigative Pathology. Likewise, copyrighted material previously 
published in another form may not be published in the Journal without express permission 
from the original copyright holder. These rules cover work previously written by the 
authors. Authors wishing to republish images, tables, or text should provide proof of such 
permission with their submission and should include the appropriate attribution in the 
figure or table legend or in the text.  
Redundant Publication. “Redundant (or duplicate) publication is publication of a paper that 
overlaps substantially with one already published in print or electronic media,” as defined 
by the Uniform Requirements for Manuscripts Submitted to Biomedical Journals 
(http://www.icmje.org). Authors must certify upon submission that the manuscript has not 
been accepted or published elsewhere and that it is not currently under review at another 
journal. Likewise, manuscripts under consideration by the Journal should not be submitted 
or published elsewhere. Publication of short abstracts in meeting proceedings does not 
violate this standard. Submissions will be ineligible for review if previously published in any 
form (print or online) other than as an abstract. This includes any public posting of raw 
manuscripts or pre-reviewed material. If there is any doubt, the authors should contact the 
Editorial Office for guidance. 
Reviewer Conduct 
Peer Review Process. Reviewers are expected to take their obligation seriously and to 
consider carefully the merits of the manuscript being assessed. Any delays in completing 
a review should be brought to the immediate attention of the Editorial Office so that we 
may assess the situation and make adjustments as needed. It is the practice of The 
American Journal of Pathology to conduct a blinded peer-review process; it is considered 
a violation of this process for peer reviewers to identify themselves or attempt to 
communicate directly with authors regarding the reviewed manuscript without the express 
permission of the Editors. The Editors will consider any deliberate ethical violation during 
peer review of a manuscript to be actionable misconduct, the potential results of which 
may be reporting of conduct to the Reviewer’s governing institution, dismissal as a peer 
reviewer for the Journal, and/or the denial to consider any future submissions to the 
Journal.  
Confidentiality. The manuscript is considered a privileged communication. When 
reviewing a manuscript for the Journal, the peer reviewer takes responsibility for 
maintaining its confidentiality. Reviewers should not retain copies of submitted 
manuscripts for personal use after completing their review. Reviewers are not allowed to 
make any use of the work described in the manuscript or take advantage of the 
knowledge gained by reviewing it until and unless it is published.  
If necessary, the manuscript may be discussed with a colleague in an effort to reach a 
decision. In such instances, the Reviewer must inform the colleague of the manuscript’s 
confidentiality and ask that they disclose any potential conflicts of interest. Information 
regarding additional assistance (colleague’s name and disclosure information as well as a 
description of the level of assistance) should be included in the “Confidential Comments to 
the Editor” portion of the online reviewer form. 
Financial Disclosure and Conflicts of Interest. Reviewers must disclose to the Editors 
any current or former relationships (eg, employment, consultancies, board membership, 
stock ownership, funding, honoraria, expert testimony, patents or royalties, travel 
reimbursements, etc) with any organization or entity having a direct financial or personal 
interest in the subject matter or materials discussed in the manuscript that could bias their 
opinions of the manuscript. Reviewers should also consider potential conflicts of interest 
arising from personal relationships or academic competition. Personal relationships 
include family members, colleagues (such as collaborators, mentors, students, or 
trainees), or associates at a Reviewer’s institution. At least three years should elapse 
between the ending of such a relationship and participation in any review. However, for 
certain relationships such as student-mentor, three years may not be sufficient time, 
especially if both investigators continue to work in the same field. Thus, Reviewers must 
err on the side of caution and decline any assignments in which the suggestion of a 
conflict or bias could be raised. By agreeing to review a manuscript, Reviewers implicitly 
affirm that any potential conflicts of interest have been disclosed to the Editors and that 
they are able to provide an impartial review of the manuscript. 
Editor Conduct 
Peer Review Process. The Editor-in-Chief, Senior Associate Editor, Associate Editors, 
and Special Associate Editor are expected to take their obligation seriously and to 
maintain the highest standard of ethics during the peer-review process. Editors should 
perform their editorial duties without bias for or against any person or institution. Any 
delays in completing the disposition of a manuscript should be brought to the immediate 
attention of the Editorial Office so that the situation may be resolved. It is considered a 
violation for Editors to communicate directly with authors regarding their manuscript 
outside of normal editorial practices. It is also a violation for the Editors to reveal 
Reviewers’ names to authors without Reviewer consent; as the Journal conducts a 
blinded peer-review process, such revelations are extremely rare. Any deliberate ethical 
violation during peer review of a manuscript is considered to be actionable misconduct, 
the potential results of which may be reporting of conduct to the Editor’s governing 
institution, dismissal as an Editor for the Journal, and/or the denial to consider any future 
submissions to the Journal.  
Editors should respect author requests to exclude specific reviewers due to prior 
collaborations, known conflicts of interest, or direct competition when such requests are 
well-founded; however, Editors have the authority to utilize such a reviewer if they feel it is 
necessary for expert peer review. Such decisions should be made only after careful 
consideration and after other options have been exhausted 
Confidentiality. The Editors are subject to the same confidentiality requirements as 
Reviewers. Further, Editors must not disclose information about manuscripts (including 
their receipt, content, status in the reviewing process, Reviewers’ comments, or final 
disposition) to anyone other than the authors, Reviewers, and Journal staff. Editors should 
not retain copies of submitted manuscripts for personal use after completing their 
disposition. Editors are not allowed to make any use of the work described in the 
manuscript or take advantage of the knowledge gained by reviewing it until and unless it is 
published.  
Financial Disclosure and Conflicts of Interest. Editors must also carefully consider 
whether there exist any current or former relationships (eg, employment, consultancies, 
board membership, stock ownership, funding, honoraria, expert testimony, patents or 
royalties, travel reimbursements, etc) with any organization or entity having a direct 
financial or personal interest in the subject matter or materials discussed in the manuscript 
that could bias their opinions of the manuscript. Editors should also consider potential 
conflicts of interest arising from personal relationships or academic competition. Personal 
relationships include family members, colleagues (such as collaborators, mentors, 
students, or trainees), or associates at the Editor’s institution. At least three years should 
elapse between the ending of such a relationship and participation in any review. 
However, for certain relationships such as student-mentor, three years may not be 
sufficient time, especially if both investigators continue to work in the same field. Thus, 
Editors must err on the side of caution and decline any assignments in which the 
suggestion of a conflict or bias could be raised. By agreeing to review a manuscript, the 
Editor implicitly affirms that conflicts do not exist. In cases where the Editor-in-Chief has a 
conflict of interest, the Senior Associate Editor or another Associate Editor will handle the 
full disposition of the manuscript.  
Staff Conduct 
Peer Review Process. When handling a manuscript for the Journal, the Journal staff is 
expected to interact courteously and respectfully with authors, Reviewers, and Editors. 
They should not misrepresent the review process to authors or Reviewers. They should  
not forge, fabricate, or alter the scientific content of Reviewer comments. They should 
ensure timely disposition of reviewed manuscripts and publication of accepted 
manuscripts.
Confidentiality. The Journal staff is subject to the same confidentiality standards as 
Editors. It is considered a violation of this confidentiality for staff to reveal Reviewer names 
or to communicate directly with authors regarding their manuscript outside of normal 
editorial practices.  
Allegations of Misconduct 
Reporting Suspected Misconduct. To maintain the integrity and high standards of the 
scientific publishing process, the Journal welcomes reporting of possible misconduct or 
other concerns related to manuscripts published or under review by the Journal. 
Suspected misconduct relating to authors, Reviewers, or Editors should be reported in 
writing to the Editorial Office at The American Journal of Pathology, 9650 Rockville Pike, 
Bethesda, Maryland, USA 20814-3993 or ajp@asip.org. Issues relating to staff conduct 
should be directed to the ASIP Executive Officer at American Society for Investigative 
Pathology, 9650 Rockville Pike, Bethesda, Maryland, USA 20814-3993 or 
mesobel@asip.org. Willful misconduct does not include incidents of honest misjudgment 
or inadvertent error. 
The anonymity of the whistleblower(s) will be maintained throughout these procedures. 
With respect to all other communications arising from examination of misconduct, the 
ability to effectively investigate and administer an allegation of scientific misconduct shall 
be carefully balanced with the need to maintain confidentiality in order to protect the rights 
and reputations of all concerned. 
Procedures for Suspected Author Misconduct. Upon written notification of possible 
author misconduct, the Editors and Editorial Office will first perform a preliminary 
evaluation to determine if there is merit to the claims. The Editors reserve the right to 
involve the Publications Committee, Executive Officer of ASIP, and/or legal counsel as 
deemed appropriate. If the manuscript is currently under review, the review process will be 
put on hold pending resolution. If the claims appear to have merit, the next step is to 
contact the authors.  
The Editor-in-Chief will contact the corresponding author and request a formal written 
response to the Editors’ concerns, and may ask to see source data, within 30 days. 
Authors are expected to cooperate fully and in good faith. Upon review of said data and 
explanation, the Editors and Editorial Office will determine whether an innocent error was 
committed (requiring publication of a Correction or Retraction) or whether further reporting 
or investigation is warranted. If needed, the authors’ institutions and/or funding agencies 
will be contacted, as it is not the responsibility of the Journal to perform such an 
investigation. During the investigation, the Journal will not receive or review new 
manuscripts from authors named in the disputed manuscript.  
The appropriate authorities at the authors’ institutions and/or funding agencies will be 
notified of the original complaint and may be asked to conduct an independent 
investigation. Once an investigation has begun, the Editors may choose to publish a Note 
of Concern informing the scientific community that an investigation is underway regarding 
the article in question. The investigation is expected to proceed in a timely manner, and 
upon completion of an investigation, the institution should quickly notify the Journal of its 
findings.  
If an institution or funding agency declines to conduct an investigation on a timely basis, or 
if an author does not have such an affiliation, the Journal may conduct its own 
investigation. 
If all authors are cleared of any wrongdoing, an unpublished manuscript may re-enter the 
review process. If a Note of Concern was published, the Journal will publish a Correction 
to rectify the matter in the public record. 
Upon receiving final determination of misconduct (including final appeal), the Journal may 
publish a Correction, Note of Concern, or Retraction, depending on the findings of the 
investigation and the effect on the paper as a whole. If misconduct is determined by the 
authors’ institutions, then the Editors may request that the authors retract their paper. If the 
authors refuse, the Journal will notify all authors of the intent to publish a Retraction, to 
which the authors have 30 days to respond. The final Retraction will describe the reason 
for retraction as well as a list of authors agreeing (and if necessary those disagreeing) with 
the retraction. For unpublished manuscripts, the manuscript may be rejected or 
acceptance may be rescinded. Depending on the severity of the misconduct committed, 
the authors may be excluded from submitting new manuscripts for a period of time.  
At any point during the course of the investigation, the authors may withdrawal their 
unpublished manuscript or request a Retraction. If this occurs prior to formal investigation, 
the Editors may still determine to inform the authors’ institutions and/or funding agencies. 
These procedures do not supersede or diminish the general authority of the Journal to 
reject a manuscript as part of the review process. 
Procedures for Suspected Editorial Misconduct (Reviewers, Editors, Staff). Upon 
written notification of possible editorial misconduct, the Editors and/or Editorial Office will 
first perform a preliminary evaluation to determine if there is merit to the claims. If the 
complaint involves an Editor or Journal staff, that person will be excluded from any review. 
The Editors reserve the right to involve the Publications Committee, Executive Officer of 
ASIP, and/or legal counsel as deemed appropriate. If the claims appear to have merit, the 
next step is to contact the person involved.  
The Editor-in-Chief or Executive Officer of the Society will contact the person involved, 
requesting a formal response to the concerns within 30 days. Upon review of said 
explanation, the Editors and Editorial Office will determine whether an innocent error was 
committed or whether further investigation or reporting is warranted. If needed, the 
person’s institution and/or funding agency will be contacted, as it is not the responsibility of 
the Journal to perform such an investigation. During the investigation, the Editor or 
Reviewer will be excluded from reviewing or submitting new manuscripts.  
The appropriate authorities at the person’s institution will be notified of the original 
complaint and may be asked to conduct an independent investigation. The investigation is 
expected to proceed in a timely manner, and upon completion of an investigation, the 
institution should quickly notify the Journal of its findings.  
Upon receiving final determination of misconduct (including final appeal), the Journal may 
publish a Note of Concern if the disposition of a manuscript(s) was affected. 
Depending on the severity of the misconduct committed, the Editor, Reviewer, or Journal 
staff may be relieved of all future Journal-related duties.  
These procedures do not supersede or diminish the general authority of the Journal to 
dismiss an Editor, Reviewer, or Journal staff. 
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